カテゴリ： GlobalData, イギリス, 企業調査

AstraZeneca Plc (AZN)-医療機器分野：企業M&A・提携分析

◆英語タイトル：AstraZeneca Plc (AZN) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011421
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月22日
◆ページ数：171
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies and through distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, the UK.

AstraZeneca Plc (AZN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
AstraZeneca Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
AstraZeneca Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
AstraZeneca Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
AstraZeneca Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
AstraZeneca Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
AstraZeneca Plc, Medical Equipment, Deal Details 15
Venture Financing 15
Definiens Raises USD20.3 Million in Venture Financing Round 15
CeraPedics Raises US$19 Million In Series C Financing 17
Definiens Raises US$13 Million In Venture Financing 18
Ambit Biosciences Secures US$30 Million In Series D-2 Financing 19
Partnerships 21
AstraZeneca Enters into Licensing Agreement with Pelago Bioscience 21
AstraZeneca Enters into Agreement with Genedata 22
Chembio Diagnostic Enters into Agreement with AstraZeneca 23
Trovagene Enters into Agreement with AstraZeneca 24
AstraZeneca Enters into Partnership with DNAnexus 25
NeoGenomics and Definiens Enter into Agreement 26
SenzaGen Enters into Agreement with AstraZeneca 27
AgPlus Diagnostics Enters into Agreement with AstraZeneca 28
Indivumed Partners with Definiens 29
Foundation Medicine Enters into Agreement with AstraZeneca 30
Definiens Partners with MolecularMD 31
MedImmune Enters into Agreement with Genisphere 32
Human Longevity Partners with AstraZeneca 33
PROOF Centre Partners with AstraZeneca 34
HighRes Biosolutions Enters into Agreement with AstraZeneca 35
Labcyte Enters into Agreement with AstraZeneca 36
AstraZeneca Enters into Research Agreement with Sutter Health 37
Myriad Genetics Expands Agreement with AstraZeneca 38
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 39
AstraZeneca Enters into Co-Development Agreement with Qiagen 40
AstraZeneca Enters into Co-Development Agreement with Roche 41
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 42
Ventana Medical Enters into Co-Development Agreement with MedImmune 43
Definiens Enters Into Agreement With Metamark For ProMark Prognostic Test 44
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 45
Oxford Cancer Biomarkers Enters Into Agreement With AstraZeneca For Biomarker Discovery 46
AstraZeneca Enters Into Research Agreement With Karolinska Institutet 47
Metamark Genetics Enters Into Co-Development Agreement With Definiens 48
Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 49
Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 50
Definiens Enters Into An Agreement With Cernostics 51
Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 52
Merger 53
AstraZeneca Rumored To Merge With Amgen 53
Debt Offering 54
AstraZeneca Prices Private Placement of 0.875% Notes Due 2021 54
Acquisition 55
Pfizer May Increase Bid to Acquire AstraZeneca 55
MedImmune Acquires Definiens for USD150 Million 57
AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 58
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 59
AstraZeneca To Acquire Remaining 10% Stake In Astrazeneca Pharma India 61
DENTSPLY International Acquires Astra Tech From AstraZeneca For US$1,800 Million 62
AstraZeneca Plc – Key Competitors 64
AstraZeneca Plc – Key Employees 65
AstraZeneca Plc – Locations And Subsidiaries 68
Head Office 68
Other Locations & Subsidiaries 68
Joint Venture 73
Recent Developments 74
Strategy And Business Planning 74
Oct 01, 2017: Molnlycke to establish R&D innovation unit in AstraZeneca’s BioVentureHub 74
Apr 25, 2017: AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK 75
Apr 04, 2016: Heptares Joins Pharma Consortium Applying State of the Art Cryo-Electron Microscopy to Advance Structure Based Drug Discovery 77
Financial Announcements 78
Nov 09, 2017: AstraZeneca Announces Year-To-Date and Q3 2017 Results 78
Jul 27, 2017: AstraZeneca Announce H1 2017 Results 86
Apr 27, 2017: AstraZeneca Announces Q1 2017 Results 95
Feb 02, 2017: Astrazeneca Announces Full-Year and Q4 2016 Results 96
Nov 10, 2016: AstraZeneca: Year-To-Date and Q3 2016 Results 97
Jul 28, 2016: AstraZeneca: H1 2016 Results 109
Apr 29, 2016: AstraZeneca announces 1st Quarter 2016 Results 120
Apr 29, 2016: AstraZeneca Announces Q1 2016 Results 131
Feb 04, 2016: Full-Year and Q4 2015 Results 133
Feb 04, 2016: AstraZeneca Full-Year and Q4 2015 Results 135
Corporate Communications 148
Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 148
Sep 05, 2017: Astrazeneca Appoints Sheri Mccoy and Deborah Disanzo to its Board 149
Aug 16, 2017: Astrazeneca Non-executive Director Retirement 151
Jul 31, 2017: AstraZeneca and MedImmune strengthen immuno-oncology leadership with appointment of two renowned experts31 July 2017 152
Jun 29, 2017: Astra Zeneca: Outcome of the meeting of board of directors held on June 29, 2017 153
May 31, 2017: AstraZeneca appoints Professor Nazneen Rahman to its Board of Directors and Science Committee 154
Mar 06, 2017: Changes to AstraZeneca Board of Directors 155
Nov 09, 2016: Change To Astrazeneca Board Of Directors 156
Sep 28, 2016: Change To Astrazeneca Board Of Directors 157
Product News 158
Sep 20, 2016: Can drag and drop cancer simulation speed up drug discovery 158
Aug 08, 2016: AstraZeneca Diabetes Diet and Lifestyle Support Program, Fit2Me, Extends to Include Cardiovascular Health 160
May 27, 2016: Blood test supports use of potential new treatment for patients with stomach cancer 161
May 05, 2016: Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released 163
Feb 16, 2016: Data analysis platform driving preclinical modelling capabilities in AstraZeneca launched to wider pharmaceutical industry 164
Other Significant Developments 165
Nov 01, 2017: CN Bio Innovations announces research collaboration with AstraZeneca to validate a new in vitro tool to predict optimised drug dosing regimens for multi-drug therapies 165
Sep 27, 2017: Inhalation Sciences gets large order from AstraZeneca 166
Jun 06, 2017: AstraZeneca Selects ArisGlobal LifeSphere Safety – Risk Management 167
Mar 31, 2017: First Collaborative Definition of Patient Centricity, Co-created by AstraZeneca with Patients and Carers, Is Published in British Medical Journal 168
Nov 29, 2016: Cytel and AstraZeneca Early Clinical Development Software Collaboration Facilitates Clinical Development Decision-Making 169
Sep 21, 2016: AstraZeneca Selects LLamasoft as Supply Chain Design Partner of Choice 170
Appendix 171
Methodology 171
About GlobalData 171
Contact Us 171
Disclaimer 171

List of Tables
AstraZeneca Plc, Medical Equipment, Key Facts, 2016 2
AstraZeneca Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
AstraZeneca Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
AstraZeneca Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
AstraZeneca Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
AstraZeneca Plc, Deals By Market, 2011 to YTD 2017 11
AstraZeneca Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Definiens Raises USD20.3 Million in Venture Financing Round 15
CeraPedics Raises US$19 Million In Series C Financing 17
Definiens Raises US$13 Million In Venture Financing 18
Ambit Biosciences Secures US$30 Million In Series D-2 Financing 19
AstraZeneca Enters into Licensing Agreement with Pelago Bioscience 21
AstraZeneca Enters into Agreement with Genedata 22
Chembio Diagnostic Enters into Agreement with AstraZeneca 23
Trovagene Enters into Agreement with AstraZeneca 24
AstraZeneca Enters into Partnership with DNAnexus 25
NeoGenomics and Definiens Enter into Agreement 26
SenzaGen Enters into Agreement with AstraZeneca 27
AgPlus Diagnostics Enters into Agreement with AstraZeneca 28
Indivumed Partners with Definiens 29
Foundation Medicine Enters into Agreement with AstraZeneca 30
Definiens Partners with MolecularMD 31
MedImmune Enters into Agreement with Genisphere 32
Human Longevity Partners with AstraZeneca 33
PROOF Centre Partners with AstraZeneca 34
HighRes Biosolutions Enters into Agreement with AstraZeneca 35
Labcyte Enters into Agreement with AstraZeneca 36
AstraZeneca Enters into Research Agreement with Sutter Health 37
Myriad Genetics Expands Agreement with AstraZeneca 38
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 39
AstraZeneca Enters into Co-Development Agreement with Qiagen 40
AstraZeneca Enters into Co-Development Agreement with Roche 41
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 42
Ventana Medical Enters into Co-Development Agreement with MedImmune 43
Definiens Enters Into Agreement With Metamark For ProMark Prognostic Test 44
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 45
Oxford Cancer Biomarkers Enters Into Agreement With AstraZeneca For Biomarker Discovery 46
AstraZeneca Enters Into Research Agreement With Karolinska Institutet 47
Metamark Genetics Enters Into Co-Development Agreement With Definiens 48
Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 49
Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 50
Definiens Enters Into An Agreement With Cernostics 51
Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 52
AstraZeneca Rumored To Merge With Amgen 53
AstraZeneca Prices Private Placement of 0.875% Notes Due 2021 54
Pfizer May Increase Bid to Acquire AstraZeneca 55
MedImmune Acquires Definiens for USD150 Million 57
AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 58
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 59
AstraZeneca To Acquire Remaining 10% Stake In Astrazeneca Pharma India 61
DENTSPLY International Acquires Astra Tech From AstraZeneca For US$1,800 Million 62
AstraZeneca Plc, Key Competitors 64
AstraZeneca Plc, Key Employees 65
AstraZeneca Plc, Subsidiaries 68
AstraZeneca Plc, Joint Venture 73

★海外企業調査レポート[AstraZeneca Plc (AZN)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • BBB Technologies Inc：企業の製品パイプライン分析
    Summary BBB Technologies Inc (BBB Tech) is a development-stage medical technology company that develops medical devices and applications that facilitate the early diagnosis of metabolic and cardiovascular disorders. It discovers and develops single-drop and mobile integrated diagnostic tools for blo …
  • Mitsubishi Logistics Corporation：企業の戦略・SWOT・財務分析
    Mitsubishi Logistics Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Logistics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Olmsted Medical Center：製薬・医療：M&Aディール及び事業提携情報
    Summary Olmsted Medical Center (OMC) is a healthcare service provider that offers patient care services. The center offers services in the areas of general surgery, podiatry, pain management, dermatology, plastic surgery, inpatient dietary services, pediatrics, diabetes education, neurology, psychia …
  • MEDITE Cancer Diagnostics Inc (MDIT)：企業の財務・戦略的SWOT分析
    MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Micropole SA (MUN)：企業の財務・戦略的SWOT分析
    Micropole SA (MUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • European Investment Bank：企業の戦略的SWOT分析
    European Investment Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • DaVita Inc (DVA)-医療機器分野：企業M&A・提携分析
    Summary DaVita Inc (DaVita), formerly DaVita HealthCare Partners Inc., is a provider of dialysis services and integrated health care delivery and management services. The company is a provider of dialysis services in the US for patients with chronic kidney failure and end-stage renal disease (ESRD). …
  • Passenger Rail Agency of South Africa：企業の戦略的SWOT分析
    Passenger Rail Agency of South Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • BioLineRx Ltd (BLRX)：製薬・医療：M&Aディール及び事業提携情報
    Summary BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company focuses mainly on cancer and immunology. Its’s product pipeline includes BL-8040, a short peptide …
  • Landis+Gyr AG (LAND)：企業の財務・戦略的SWOT分析
    Landis+Gyr AG (LAND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Ping An Insurance (Group) Company of China, Ltd.：企業の戦略・SWOT・財務情報
    Ping An Insurance (Group) Company of China, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ping An Insurance (Group) Company of China, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …
  • J.Crew Group, Inc.：企業の戦略・SWOT・財務情報
    J.Crew Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary J.Crew Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The Saudi Investment Bank：企業の戦略・SWOT・財務分析
    The Saudi Investment Bank - Strategy, SWOT and Corporate Finance Report Summary The Saudi Investment Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Moog Inc (MOG.A)：企業の財務・戦略的SWOT分析
    Moog Inc (MOG.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Airasia Group Berhad
    Airasia Group Berhad - Strategy, SWOT and Corporate Finance Report Summary Airasia Group Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Nutra Pharma Corp (NPHC)：企業の財務・戦略的SWOT分析
    Nutra Pharma Corp (NPHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Companhia Energetica de Minas Gerais – CEMIG：企業の戦略・SWOT・財務分析
    Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report Summary Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • DNAtrix Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary DNAtrix Inc (DNAtrix) is an independent clinical stage, biotechnology company that focuses on the development of oncolytic immunotherapies for cancer. The company’s portfolio of pipeline products includes DNX-2401, a modified common cold virus that targets and kills cancer cells selectively; …
  • OBJ Ltd (OBJ)：企業の財務・戦略的SWOT分析
    Summary OBJ Ltd (OBJ) is a developer of magnetic micro-array drug and ingredient delivery technologies. The company offers services such as drug or ingredient profiling in skin, laboratory facilities and capabilities, formulation development, product development, product optimisation, and pre-commer …
  • Intrexon Corp (XON)：企業の財務・戦略的SWOT分析
    Summary Intrexon Corp (Intrexon), formerly Genomatix Corp is a synthetic biology service provider. The company operates through its divisions and units such as cell engineering, data sciences and computational biology, information technology (IT), actobiotics, molecular engineering, agricultural bio …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆